AR066168A1 - Formulaciones galenicas de compuestos organicos - Google Patents
Formulaciones galenicas de compuestos organicosInfo
- Publication number
- AR066168A1 AR066168A1 ARP080104137A ARP080104137A AR066168A1 AR 066168 A1 AR066168 A1 AR 066168A1 AR P080104137 A ARP080104137 A AR P080104137A AR P080104137 A ARP080104137 A AR P080104137A AR 066168 A1 AR066168 A1 AR 066168A1
- Authority
- AR
- Argentina
- Prior art keywords
- percent
- minutes
- oral dose
- pharmaceutical combination
- dose pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a una combinacion farmacéutica de dosis oral fija, la cual comprende: a) una cantidad terapéuticamente efectiva de Alisquireno, o una sal farmacéuticamente aceptable del mismo, b) una cantidad terapéuticamente efectiva de Valsartan, o una sal farmacéuticamente aceptable del mismo, en donde la combinacion farmacéutica de dosis oral fija muestra una disolucion in vitro del componente a) del 80 por ciento o menos después de 10 minutos, y del 98 por ciento o menos después de 20 minutos, y un perfil de disolucion del componente b) del 25 por ciento o más después de 30 minutos, y del 40 por ciento o más después de 60 minutos, a un pH de 4,5. Reivindicacion 26: El uso de la combinacion farmacéutica de dosis oral fija de acuerdo con cualquiera de las reivindicaciones anteriores, para el tratamiento de hipertension, insuficiencia cardíaca congestiva, angina, infarto de miocardio, arterioesclerosis, nefropatía diabética, miopatía cardíaca diabética, insuficiencia renal, enfermedad vascular periférica, hipertrofia de ventrículo izquierdo, disfuncion cognitiva, embolia, dolor de cabeza, e insuficiencia cardíaca cronica, en particular hipertension.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97590907P | 2007-09-28 | 2007-09-28 | |
US97592507P | 2007-09-28 | 2007-09-28 | |
US97590107P | 2007-09-28 | 2007-09-28 | |
US97591907P | 2007-09-28 | 2007-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066168A1 true AR066168A1 (es) | 2009-07-29 |
Family
ID=40377183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104137A AR066168A1 (es) | 2007-09-28 | 2008-09-24 | Formulaciones galenicas de compuestos organicos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100209480A1 (es) |
EP (1) | EP2205233A2 (es) |
JP (1) | JP2010540547A (es) |
KR (1) | KR20100063090A (es) |
CN (1) | CN101808631A (es) |
AR (1) | AR066168A1 (es) |
AU (1) | AU2008309058B2 (es) |
BR (1) | BRPI0817442A2 (es) |
CA (1) | CA2698330A1 (es) |
CL (1) | CL2008002829A1 (es) |
CO (1) | CO6270217A2 (es) |
EC (1) | ECSP10010052A (es) |
MA (1) | MA31706B1 (es) |
MX (1) | MX2010003441A (es) |
PE (1) | PE20090654A1 (es) |
TN (1) | TN2010000135A1 (es) |
TW (1) | TW200924737A (es) |
WO (1) | WO2009045795A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091203A1 (es) * | 2007-09-28 | 2009-09-11 | Novartis Ag | Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
EP2408433A1 (en) * | 2009-03-20 | 2012-01-25 | Novartis AG | Pharmaceutical composition comprising aliskiren |
WO2010107971A1 (en) * | 2009-03-20 | 2010-09-23 | Novartis Ag | Galenical formulations of a fixed dose combination of valsartan and aliskiren |
AR080683A1 (es) * | 2010-03-16 | 2012-05-02 | Novartis Ag | Composiciones farmaceuticas de aliskiren y metodos de administracion |
TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
CN101926793B (zh) * | 2010-08-05 | 2012-08-15 | 成都自豪药业有限公司 | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 |
KR20140076621A (ko) * | 2011-10-12 | 2014-06-20 | 다우 글로벌 테크놀로지스 엘엘씨 | 사출 성형된 투여형 |
JP2015504878A (ja) * | 2011-12-26 | 2015-02-16 | ノバルティス アーゲー | 錠剤及び有核剤 |
CN103349652B (zh) * | 2013-05-11 | 2014-11-19 | 辽宁大学 | 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
MY144477A (en) * | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
US20080085914A1 (en) * | 2004-10-08 | 2008-04-10 | David Louis Feldman | Use Of Organic Compounds |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
CN101166523A (zh) * | 2005-04-27 | 2008-04-23 | 诺瓦提斯公司 | 治疗动脉粥样硬化的方法 |
-
2008
- 2008-09-24 CN CN200880108860A patent/CN101808631A/zh active Pending
- 2008-09-24 EP EP08835022A patent/EP2205233A2/en not_active Withdrawn
- 2008-09-24 AU AU2008309058A patent/AU2008309058B2/en not_active Ceased
- 2008-09-24 AR ARP080104137A patent/AR066168A1/es not_active Application Discontinuation
- 2008-09-24 BR BRPI0817442-3A patent/BRPI0817442A2/pt not_active IP Right Cessation
- 2008-09-24 KR KR1020107006603A patent/KR20100063090A/ko not_active Application Discontinuation
- 2008-09-24 CL CL2008002829A patent/CL2008002829A1/es unknown
- 2008-09-24 TW TW097136690A patent/TW200924737A/zh unknown
- 2008-09-24 WO PCT/US2008/077416 patent/WO2009045795A2/en active Application Filing
- 2008-09-24 PE PE2008001660A patent/PE20090654A1/es not_active Application Discontinuation
- 2008-09-24 CA CA2698330A patent/CA2698330A1/en not_active Abandoned
- 2008-09-24 JP JP2010527091A patent/JP2010540547A/ja not_active Withdrawn
- 2008-09-24 MX MX2010003441A patent/MX2010003441A/es not_active Application Discontinuation
- 2008-09-24 US US12/678,877 patent/US20100209480A1/en not_active Abandoned
-
2010
- 2010-03-17 MA MA32701A patent/MA31706B1/fr unknown
- 2010-03-26 EC EC2010010052A patent/ECSP10010052A/es unknown
- 2010-03-26 TN TNP2010000135A patent/TN2010000135A1/fr unknown
- 2010-04-19 CO CO10045487A patent/CO6270217A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2010003441A (es) | 2010-04-21 |
WO2009045795A2 (en) | 2009-04-09 |
KR20100063090A (ko) | 2010-06-10 |
BRPI0817442A2 (pt) | 2015-06-16 |
JP2010540547A (ja) | 2010-12-24 |
AU2008309058A1 (en) | 2009-04-09 |
WO2009045795A3 (en) | 2009-07-16 |
CA2698330A1 (en) | 2009-04-09 |
ECSP10010052A (es) | 2010-04-30 |
TN2010000135A1 (en) | 2011-09-26 |
CL2008002829A1 (es) | 2009-06-26 |
PE20090654A1 (es) | 2009-06-27 |
EP2205233A2 (en) | 2010-07-14 |
CO6270217A2 (es) | 2011-04-20 |
TW200924737A (en) | 2009-06-16 |
MA31706B1 (fr) | 2010-09-01 |
CN101808631A (zh) | 2010-08-18 |
AU2008309058B2 (en) | 2012-08-09 |
US20100209480A1 (en) | 2010-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
ES2651287T3 (es) | Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral | |
DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
ECSP12012048A (es) | Antagonistas del receptor mineralcorticoide no esteroidal | |
CO6382125A2 (es) | Inhibidores de proteína quinasa | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
MX344109B (es) | Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico. | |
RU2010116526A (ru) | Фармацевтическая комбинация алискирена и валсартана | |
CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
EA201200037A1 (ru) | Терапевтические комбинации никотиновой кислоты и мелдония | |
AR073651A1 (es) | Formulaciones galenicas de compuestos organicos | |
RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
JP2011527984A5 (es) | ||
AR075880A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y valsartan. uso. metodo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |